English
Regional settings| Spread | 0.28 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.022099% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.000123% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | EUR | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Germany | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 67.61 |
| Open | 67.66 |
| 1-Year Change | 244.85% |
| Day's Range | 67.61 - 67.66 |
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
BRIEF: For the fiscal year ended 31 December 2021, MorphoSys AG revenues decreased 45% to EUR179.6M. Net loss totaled EUR514.5M vs. income of EUR97.9M. Revenues reflect USA and Canada segment decrease of 51% to EUR156.3M. Net loss reflects Impairment - Goodwill increase from EUR2.1M to EUR230.7M (expense), Other R&D increase of 80% to EUR153.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from EUR3.01 to -EUR15.40.
12/2008, 3-for-1 stock split.
